大剂量阿托伐他汀钙对内囊预警综合征进展为脑梗死患者血清S100B蛋白及预后的影响

Effect of large dose of atorvastatin on serum S100B protein and prognosis in patients with stroke coming from capsular warning syndrome

目的观察大剂量阿托伐他汀对内囊预警综合征进展为脑梗死患者血清S100B蛋白水平及预后的影响。方法随机将发病24h内入院的内囊预警综合征进展为脑梗死患者30例分为对照组和阿托伐他汀组(阿托伐他汀80mg/d,连续用药14d)。治疗前后检测血清S100B蛋白水平,应用美国国立卫生研究院卒中量表(NIHSS)及Barthel指数(BI)记分法对入院后当天及3个月时行神经功能缺损程度进行评分。结果治疗前血清S100B蛋白与当时及3个月时病情严重性显著相关(r=0.721,r=-0.635,P均<0.001;r=0.561,r=-0.623,P均<0.001)。治疗后阿托伐他汀组血清S100B蛋白水平下降,且与对照组相比,差异有显著性(P=0.009)。各组入院时神经功能缺失程度评分与3个月后相比,差异有显著性(P<0.001,P<0.001),但不同组之间相比无明显差异。结论短期应用大剂量阿托伐他汀可以降低内囊预警综合征进展为脑梗死患者血清S100B蛋白水平,但对其3个月的预后无明显改善作用。

Objective To observe the effect of large dose of atorvastatin on S100B protein levels and prognosis in patients with stroke coming from capsular warning syndrome.Methods 30 patients with stroke coming from capsular warning syndrome were randomly divided into two equal groups.Control group was given general treatment and Atorvastain group was given 80mg/d of atorvastain except that.The levels of serum S100B protein were detected before and after treatment.Never function was evaluated by the National Institutes of Health Stroke Scale（NIHSS） score and the Barthel Index（BI） score at admission and 3 months after admission.Results The levels of serum S100B protein were correlated significantly with severity and prognosis of cerebral infarction（r=0.721,r=-0.635,P〈0.001;r=0.561,r=-0.623,P〈0.001）.The levels of serum S100B protein in atorvastain group significantly decreased compared with those in control group（P=0.009）.Neurological functional deficit scales in the two groups were significantly improved after 3 months（P〈0.001,P〈0.001）,but there was no statistical difference in two groups.Conclusion Large dose of atorvastain can rapidly and safely reduce the serum level of S100B protein,but there is no significant improvement in 3-month prognosis.